Ixekizumab: A Promising Treatment for Plaque Psoriasis

Introduction

Recent findings from three clinical trials suggest that ixekizumab could be a viable alternative for patients suffering from moderate to severe plaque psoriasis. Importantly, this treatment may benefit individuals who have previously not responded to similar therapies.

Understanding Plaque Psoriasis

Plaque psoriasis is an autoimmune skin disorder that can significantly impact the quality of life for those diagnosed. When the condition manifests in its moderate or severe forms, patients may face mental, social, and physical health challenges. Due to the unpredictable nature of psoriasis and other autoimmune diseases, a diverse range of treatment options is essential.

Treatment Options for Plaque Psoriasis

One of the treatment modalities for moderate to severe plaque psoriasis involves the use of biologicals, which are antibodies that target inflammatory cytokines. These therapies are typically reserved for patients who have not had adequate responses to standard treatments or for whom standard therapies are unsuitable.

Clinical Trials for Ixekizumab

Eli Lilly, the pharmaceutical company behind ixekizumab, has submitted evidence for its new biological treatment to the UK’s National Health Service (NHS) appraisal committee for evaluation. This submission includes an economic model assessing the cost-effectiveness of ixekizumab.

The supporting data comes from three trials, known as UNCOVER 1, 2, and 3, involving a total of 3,866 participants with moderate to severe plaque psoriasis. The first trial compared ixekizumab to a placebo, while the second and third trials compared it to etanercept, an existing treatment for plaque psoriasis, as well as a placebo.

Evaluating Clinical Effectiveness

The clinical effectiveness of ixekizumab was assessed using the Psoriasis Area and Severity Index (PASI), which measures plaque size, redness, and thickness, alongside the Dermatology Life Quality Index (DLQI). An adequate response to treatment is defined as a minimum 75% reduction in PASI score or a 50% reduction in PASI score combined with a 5-point decrease in DLQI after 12 weeks of treatment.

Results from all three trials indicated that ixekizumab outperformed both placebo and etanercept. Notably, it also yielded better outcomes for patients who had previously been treated with other biologicals. Furthermore, ixekizumab’s tolerability was found to be comparable to that of other biological treatments, alleviating concerns regarding long-term safety.

Meta-Analysis Findings

A meta-analysis was conducted to compare ixekizumab with several currently utilized biological treatments, including adalimumab, ustekinumab, secukinumab, and infliximab. The analysis revealed that ixekizumab had a significantly higher probability of achieving a 75% reduction in PASI score within 12 weeks compared to adalimumab and ustekinumab, while its effectiveness was similar to that of infliximab and secukinumab.

Conclusion

In conclusion, the evidence supports ixekizumab as an effective treatment option for patients with moderate to severe plaque psoriasis. Given the favorable economic evaluation, ixekizumab will be made available through the NHS, aligning with its current accessibility in various regions worldwide.

Written By

Saran Amin, MPharm

Related Topics

– Targeting VEGFA signaling in the skin epidermis as a new treatment for psoriasis
– How a lipid drug may be used as a new psoriasis treatment
– Psoriasis and high blood pressure may increase risk of needing heart surgery
– Psoriasis and Diet: What are the effects of various dietary recommendations?
– Topical Therapies for Psoriasis: Foam or Gel?
– Nonalcoholic Fatty Liver Disease Progression in Psoriasis Patients
– Therapy for Psoriasis May Not be Triggering Inflammatory Bowel Disease